Discover TESSA® Technology

For Scalable, Versatile, Economical AAV Manufacture

Learn how TESSA Technology can increase overall AAV yields by ~10 fold while providing a more economical model than triple plasmid transfection. Standard results also deliver a high % full capsid rate and very strong safety profile with no adenoviral contamination.

WuXi Advanced Therapies will present a brief overview of Tessa Technology at ASGCT’s Annual 2024 Meeting on May 8th. Please complete the form below to receive your copy of the slides.

Please complete the form below to receive the downloads listed via email

"*" indicates required fields

Mailing List
In addition to sending a copy of the presentation please contact me about the following*
Select all that apply
This field is for validation purposes and should be left unchanged.
Ameba Creative StudioAmeba Creative Studio